Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable' - 2Purchases of iPhone 17 Pro soar across Gaza amid 'limited' humanitarian aid
- 3Russia provided Iran with list of Israeli energy targets, Ukrainian intelligence finds
- 4FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 5Terminal cancer diagnosis announced by JFK's granddaughter
- Israeli tourist data from 2025 misrepresented as mass exodus to Thailand
- Must-See Attractions in France
- Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
- Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- One ant for $220: the new frontier of wildlife trafficking
- US FDA grants market authorization to six on! PLUS nicotine pouch products
- No more attempts to free whale stranded off Germany, officials say
- Unsold Rams May Be Less expensive Than You Suspect
- Overlooked infertility care should be part of national health services, says WHO
